{"id":4044,"date":"2020-10-05T13:13:09","date_gmt":"2020-10-05T13:13:09","guid":{"rendered":"https:\/\/www.norron.com\/?p=4044"},"modified":"2020-10-06T14:19:47","modified_gmt":"2020-10-06T14:19:47","slug":"extraordinary-success-for-norrons-holding-vaccibody","status":"publish","type":"post","link":"https:\/\/norron.com\/en\/extraordinary-success-for-norrons-holding-vaccibody\/","title":{"rendered":"Extraordinary\u00a0success for\u00a0Norron’s\u00a0holding Vaccibody\u00a0"},"content":{"rendered":"

Extraordinary<\/span><\/b>\u00a0success for\u00a0<\/span><\/b>Norron’s<\/span><\/b>\u00a0holding Vaccibody<\/span><\/b>\u00a0<\/span><\/p>\n

\"\"<\/span><\/p>\n

Since December 2016,\u00a0<\/span>Norron<\/span>\u00a0has invested in and supported the Norwegian biotech company\u00a0<\/span>Vaccibody<\/span>. Th<\/span>is<\/span>\u00a0holding was the first<\/span>\u00a0one<\/span>\u00a0we invested in\u00a0<\/span>using\u00a0<\/span>our<\/span>\u00a0<\/span>unlisted holding\u00a0<\/span>strategy<\/span>.<\/span>\u00a0The reason for our\u00a0<\/span>initial\u00a0<\/span>investment was the very promising\u00a0<\/span>fundamental\u00a0<\/span>research that the company was able to present at that stage in the pre-clinical phase concerning personalized cancer vaccines.\u00a0<\/span>Norron’s<\/span>\u00a0original investment amounted to NOK 45 million. Over the years, we have realized values of NOK 145 million,\u00a0<\/span>I\u00a0<\/span>e<\/span>\u00a0the entire value of the original investment and an additional NOK 100 million in value increase. At present, we are pleased that we have followed the company from unlisted holdings, to listing on the OTC market, and as of this week, listing on the Merkur market, which is regulated by the Oslo Stock Exchange. At present, the value of\u00a0<\/span>Norron’s<\/span>\u00a0position amounts to NOK 240\u00a0<\/span>million, and<\/span>\u00a0corresponds to an ownership of approximately 1.4 percent in the company. For our unit holders, the investment has had an\u00a0<\/span>amazing<\/span>\u00a02000 percent development, or an<\/span>\u00a0average<\/span>\u00a0annual return of 123%.<\/span>\u00a0<\/span><\/p>\n

The company’s unique position in personalized cancer vaccines was validated on September 29, 2020, through the announcement of a global research collaboration with Genentech, part of the Roche Group. Through the collaboration, Genentech undertakes t<\/span>he<\/span>\u00a0develop<\/span>ment<\/span>\u00a0and financ<\/span>ing<\/span>\u00a0<\/span>of\u00a0<\/span>one of the projects from\u00a0<\/span>Vaccibody’s<\/span>\u00a0technology platform for commercialization. The agreement is currently worth approximately NOK 7 billion, excluding the future royalty income that accrues to\u00a0<\/span>Vaccibody’s<\/span>\u00a0shareholders.<\/span>\u00a0<\/span><\/p>\n

The above is of course extremely gratifying for us and our shareholders, but what makes this particular investment\u00a0<\/span>extra\u00a0<\/span>special is the company’s success in cancer treatment, which benefits many hard-hit patients and their loved ones. Using\u00a0<\/span>Vaccibody’s<\/span>\u00a0personalized cancer vaccine, studies on patients with developed cancer, wh<\/span>o<\/span>\u00a0ha<\/span>ve<\/span>\u00a0been under long-term traditional<\/span>\u00a0cancer<\/span>\u00a0treatment, ha<\/span>ve<\/span>\u00a0shown\u00a0<\/span>significant<\/span>ly improved disease progression.<\/span>\u00a0<\/span><\/p>\n

We want to highlight this investment to our customers and partners\u00a0<\/span>since<\/span>\u00a0it symbolizes much of what we want to achieve in our active management, namely to identify quality companies at an early stage,\u00a0<\/span>t<\/span>h<\/span>at<\/span>\u00a0can contribute significantly to our customers’ return<\/span>s<\/span>, and through our support,\u00a0<\/span>are able to<\/span>\u00a0promote a positive development<\/span>\u00a0<\/span>for<\/span>\u00a0society and\u00a0<\/span>business, in\u00a0<\/span>a range of<\/span>\u00a0different\u00a0<\/span>field<\/span>s.<\/span>\u00a0<\/span><\/p>\n

\u00a0<\/span>Vaccibody<\/span>\u00a0is<\/span>\u00a0<\/span>a holding<\/span>\u00a0in the following funds managed by\u00a0<\/span>Norron<\/span>\u00a0Asset Management:<\/span>\u00a0<\/span>Norron<\/span>\u00a0Target,\u00a0<\/span>Norron<\/span>\u00a0Select and, our latest addition,\u00a0<\/span>Norron<\/span>\u00a0Sustainable Equity.<\/span>\u00a0<\/span>\u00a0<\/span><\/p>\n

Please feel<\/span>\u00a0free to contact us if you\u00a0<\/span>would like to know more about\u00a0<\/span>our\u00a0<\/span>approach<\/span>\u00a0to\u00a0<\/span>active management and\u00a0<\/span>our additional\u00a0<\/span>holdings that\u00a0<\/span>focus on sustainability<\/span>.<\/span>\u00a0<\/span><\/p>\n

Kind regards,\u00a0<\/span>\u00a0<\/span><\/p>\n

Norron Asset Management<\/span>
\nE:\u00a0<\/span>info@norron.com<\/span>
\n<\/a>T: 08 555<\/span>\u00a0<\/span>069<\/span>40<\/span>\u00a0<\/span><\/p>\n

\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

Extraordinary\u00a0success for\u00a0Norron’s\u00a0holding Vaccibody\u00a0 Since December 2016,\u00a0Norron\u00a0has invested in and supported the Norwegian biotech company\u00a0Vaccibody. This\u00a0holding was the first\u00a0one\u00a0we invested in\u00a0using\u00a0our\u00a0unlisted holding\u00a0strategy.\u00a0The reason for our\u00a0initial\u00a0investment was the very promising\u00a0fundamental\u00a0research that the…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[35],"tags":[],"class_list":{"0":"post-4044","1":"post","2":"type-post","3":"status-publish","4":"format-standard","6":"category-news"},"_links":{"self":[{"href":"https:\/\/norron.com\/en\/wp-json\/wp\/v2\/posts\/4044","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/norron.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/norron.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/norron.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/norron.com\/en\/wp-json\/wp\/v2\/comments?post=4044"}],"version-history":[{"count":1,"href":"https:\/\/norron.com\/en\/wp-json\/wp\/v2\/posts\/4044\/revisions"}],"predecessor-version":[{"id":4045,"href":"https:\/\/norron.com\/en\/wp-json\/wp\/v2\/posts\/4044\/revisions\/4045"}],"wp:attachment":[{"href":"https:\/\/norron.com\/en\/wp-json\/wp\/v2\/media?parent=4044"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/norron.com\/en\/wp-json\/wp\/v2\/categories?post=4044"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/norron.com\/en\/wp-json\/wp\/v2\/tags?post=4044"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}